Alithea Bio Scores Double Victory at VivaTech 2026: Winning Jury’s “Tech for Change” and Audience Favorite Awards for Breakthrough in Preclinical Safety

[PARIS / BERLIN / FREIBURG] — 23.6.2026

Fanny Giannou, CEO of Alithea Bio, accepting the Tech for Change Award, and the Audience Award at VivaTech 2026, Paris.

Deep-tech biotech innovator Alithea Bio has achieved a spectacular double victory at VivaTech 2026, Europe’s largest startup and tech event, taking home both the coveted “Tech for Change” Jury Prize and the Audience Favorite Award. Selected by an elite panel of global investors and corporate leaders—and backed by overwhelming public support—the awards recognize Alithea Bio’s pioneering work in eliminating toxicity risks at the preclinical stage to dramatically increase clinical trial success rates.

Historically, promising cancer therapies and vaccines fail during human trials due to unforeseen toxicities and adverse immune reactions that standard models miss. Alithea Bio’s proprietary platform, HLA-Compass AI, solves this multi-billion-dollar bottleneck during preclinical development by mapping complex Human Leukocyte Antigen (HLA) interactions. Unlike purely digital AI startups, Alithea Bio utilizes a unique hybrid model—combining its own active wet lab with an advanced computational engine to accurately predict and filter out toxicity risks long before an asset ever enters human clinical trials.

The company’s commercial traction matches its scientific breakthrough. Fully bootstrapped to date, Alithea Bio amassed 22 million proprietary datapoints and generated €1.6M in revenue in 2025 through active preclinical validation partnerships with global pharmaceutical leaders.

“Sweeping both the jury and audience awards at VivaTech is an incredible validation of our mission, our impact and our scalable commercial model. Too many life-saving therapies are derailed late in development because traditional preclinical models fail to predict human toxicity. HLA-Compass isn’t just about saving pharma companies millions in failed trials; it’s about ensuring that only the safest, most precise assets advance to human clinical trials. The crowd and the jury both sent a clear message: the industry is ready for this change.”

The double accolade comes at a pivotal moment of global scaling for Alithea Bio. The company is currently expanding its strategic partnerships with global pharmaceutical leaders and launching an institutional Seed funding round to transition its proven data-service capabilities into a highly scalable software platform while expanding its footprint into the US market.

For more information about Alithea Bio and the HLA-Compass platform, visit www.alithea-bio.com or contact news@alithea-bio.com.

— END —